KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Treasury Shares: 2012-2024

Historic Treasury Shares for Ionis Pharmaceuticals (IONS) over the last 13 years, with Dec 2024 value amounting to $3.8 million.

  • Ionis Pharmaceuticals' Treasury Shares rose 18.28% to $3.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.8 million, marking a year-over-year increase of 18.28%. This contributed to the annual value of $3.8 million for FY2024, which is 18.28% up from last year.
  • As of FY2024, Ionis Pharmaceuticals' Treasury Shares stood at $3.8 million, which was up 18.28% from $3.2 million recorded in FY2023.
  • Ionis Pharmaceuticals' Treasury Shares' 5-year high stood at $3.8 million during FY2024, with a 5-year trough of $2.4 million in FY2020.
  • Over the past 3 years, Ionis Pharmaceuticals' median Treasury Shares value was $3.2 million (recorded in 2023), while the average stood at $3.3 million.
  • Data for Ionis Pharmaceuticals' Treasury Shares shows a peak YoY surged of 343.74% (in 2020) over the last 5 years.
  • Ionis Pharmaceuticals' Treasury Shares (Yearly) stood at $2.4 million in 2020, then rose by 10.28% to $2.6 million in 2021, then rose by 5.65% to $2.8 million in 2022, then increased by 17.10% to $3.2 million in 2023, then climbed by 18.28% to $3.8 million in 2024.